HANetf has introduced the Arrow Bitcoin EUR Hedged ETC, the first euro-hedged Bitcoin exchange-traded commodity in Europe, listed on Euronext Paris and Xetra. This product allows euro-based investors to gain Bitcoin exposure without the risk of euro-dollar currency fluctuations by using HSBC for daily FX hedging. With a total expense ratio of 49 basis points plus a small daily hedging cost, it aims to isolate Bitcoin price movements from currency volatility, making it attractive for institutional investors familiar with hedged gold and equity products. This launch marks a significant step in integrating crypto assets into traditional financial systems and could expand the European crypto ETP market beyond its current $12 billion asset base.
The launch of HANetf's euro-hedged Bitcoin ETP in Europe is notable amid a diverse cryptocurrency market on Pluang. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Sep 30, 2026 02:42 WIB: out of 50 priced major cryptocurrencies, 27 rose and 22 fell today. Key movers include AXS (Axie Infinity) at Rp20.502 with a 1-day change of +3.62%, LINK (Chainlink) at Rp262.625 down 3.35%, and GRT (The Graph) at Rp531 down 3.10%.
Micron Technology is set to report record quarterly revenue of up to $51.33 billion, fueled by strong demand for high-bandwidth memory in the AI market. Earnings per share are expected to jump significantly to around $31.72, compared to $3.03 last ye...
Sangoma Technologies reported a smaller-than-expected loss with an EPS of -$0.08, beating analyst estimates of -$2.19, though its revenue of $48.55 million slightly missed expectations. Despite ongoing profitability challenges reflected in a negative...
Iovance Biotherapeutics has increased its full-year 2026 revenue guidance to $410-$420 million, reflecting nearly 60% growth driven by strong U.S. demand for its cancer therapy Amtagvi, which generated $91 million in Q2 sales. Analyst Joseph Pantgini...
uniQure's stock fell sharply by 37% following a four-year update on its AMT-130 gene therapy for Huntington's disease, which showed reduced effectiveness from 80% at three years to 44% at four years, failing to reach statistical significance. Despite...
Altrova Health Inc. has settled C$215,000 of outstanding debt by issuing 3,583,333 common shares at a price of C$0.06 per share to three creditors. This debt settlement did not bring in cash but helped reduce the company's liabilities and preserve ca...
